Events are unfolding that play towards the strength of the PYC peptide delivery system or more specifically CPPs. In fact a watershed moment may have arrived that will dramatically swing the pendulum away from AAV to peptide or for that matter any other delivery system that's not AAV.
An article published in Endpoints News dated 23 August 2021 titled Capping AAV dose? Tweaking gene therapy trials? New Animal models? FDA poses far-reaching questions for experts, discusses news of far reaching consequences for biotech/pharma in the gene therapy and RNA therapeutics space. The FDA is meeting to discuss problems associated with AAV with the focus upon toxicity. The problems go to the very heart of whether the continued use of high doses of AAV vectors is at all viable i.e. could AAV vectors be intrinsically dangerous.
PYC Price at posting:
14.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)